Industrial and Tech Stocks Lower: Titomic, Sprintex and 333D in Focus

Sonal Goyal

03 November 2026 04:30 PM AEDT

Industrial and Tech Stocks Lower: Titomic, Sprintex and 333D in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

333D (ASX:T3D) fell 25.71% to 2.6 cents during the 3 November 2026 session, the steepest fall in this group.
Titomic (ASX:TTT) traded at 9.1 cents, down 8.08%, and Sprintex (ASX:SIX) traded at 5.7 cents, down 9.52%.
The three companies reported quarterly updates in late October, each dated before 3 November.
The S&P/ASX 200 eased about 0.12% to 8,846.20 in the same session.

Three small caps lower in one session

Three ASX companies with industrial or technology exposure finished lower in the 3 November 2026 session. 333D Ltd (ASX:T3D) fell 25.71% to 2.6 cents, Sprintex Ltd (ASX:SIX) dropped 9.52% to 5.7 cents and Titomic Ltd (ASX:TTT) slipped 8.08% to 9.1 cents. The S&P/ASX 200 eased about 0.12%, or 10.30 points, to 8,846.20 over the same session. The companies cover digital imaging software, water treatment systems and advanced coatings.

333D (ASX:T3D)

333D's quarterly report, released on 29 October 2026, showed cash receipts from customers of $639,558 and a net operating cash outflow of $62,827, down from $250,085. Total cash and digital asset holdings were $523,880, and the company said its clinical imaging software completed a model Training milestone.

Sprintex (ASX:SIX)

Sprintex's quarterly report, released on 29 October 2026, reported an order book of A$41.1 million and continued on-farm testing of its Mest Water systems. After quarter end, it signed a co-development agreement with Bosiwei, targeting up to 500 systems a year, though those volumes are not contracted.

Titomic (ASX:TTT)

Titomic's quarterly report, released on 29 October 2026, said it raised A$16.5 million in Equity and received EXIM Loan approval for US$10.3 million for its Huntsville expansion. Orders of more than A$11.8 million were secured since September, and a US redomiciliation is expected by the end of November, subject to approvals.

Sector context

Water treatment, defence Manufacturing and digital imaging software all depend on contract timing, customer validation and government funding. Smaller companies often report order flow in stages rather than as steady revenue.

Risks

Sprintex's Bosiwei volumes are not contracted, and its order book depends on testing outcomes. Titomic's delivery schedules run into 2027 and its redomiciliation needs approvals. 333D's clinical software is still before commercialisation.

What to watch next

Investors will be watching Sprintex's conversion of testing into firm orders, Titomic's redomiciliation and Tinker delivery schedule, and 333D's validation of its clinical software.

The Final Word

The three companies traded lower on 3 November 2026. Their latest reports covered order flow, financing and cash burn, with the next milestones still to come.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.